Table 4.
Developments of skeletal-related events in breast cancer patients in included studies.
| Refs. | SREs N(%) | SREFI (range) yr | BP N (%) | PF N (%) | SCC N (%) | TIH N (%) | RT N (%) | Sur N (%) | First-line Therapy for BM N (%) |
|---|---|---|---|---|---|---|---|---|---|
| Cetin K [21] | NA | NA | NA | 67(3) | 63(3) | NA | 484(20) | 63(3) | RT 484(20), Sur 63(3) |
| Dibekoglu C [22] | NA | 3.41 (0.66–12.67) | NA | 41 (30) | NA | NA | NA | NA | BMA 139(100), HT 69(50), ChT 18(13), ChT+HT 42(30), MT 2(1.4) |
| Bollen L [23] | NA | NA | NA | NA | NA | NA | 67 (60) | 21(19) | RT 69(62), Sur 21(19) |
| Foerster R [24] | NA | NA | NA | 6 (7) | NA | NA | 92 (100) | NA | BMA 85(92), RT 92(100), ChT 53(58) |
| Steinauer K [26] | NA | NA | NA | 35 (15) | NA | NA | 137 (58) | 66(28) | BMA 170(71), RT 108(46), Sur 37(16), RT+Sur 29(12), ChT 49(21), HT 60(25), ChT+HT 100(42) |
| Yamashiro H [27] | 133(68.9) | 0.068 | NA | NA | NA | NA | NA | NA | NA |
| Arican A [28] | NA | NA | 22(2) | NA | NA | NA | 580(57) | 36(4) | BMA 985(96), RT 580(57), Sur 36(4), ChT 271(26), HT 107(10) |
| Kuchuk I [29] | NA | 0.15 | 71(40) | 53(35) | 14(9) | 18(12) | 132(85) | 20(13) | BMA 155(88), RT 132(85), Sur 20(13), ChT 119 (68), HT 135(77), MT 25(13) |
| Sung GA [31] | NA | NA | NA | NA | NA | NA | 80(73) | NA | BMA 45(41), RT 80(73), ChT 99(90), HT 45(41) |
| Sathiakumar N [32] | 3319(46) | NA | 785(29) | 303(11) | NA | 1616(59) | 29(1) | RT 1616(59), Sur 29(1) | |
| Sun JL [34] | NA | NA | NA | NA | NA | NA | 47(32) | NA | BMA 100(69), RT 19(13), ChT 27(19), RT+ChT 15(10), RT+HT 13(9), HT 54(37), ChT+MT 6(4) |
| Trinkaus M [36] | NA | 0.85a, 2.4b | 49(56) | 10(12) | 3(3) | 8(9) | 69(79) | NA | NA |
| Cazzaniga ME [39] | NA | 205 (45) | 5 (1) | NA | 2 (0.4) | NA | NA | BMA 310(68), RT 172(38), ChT 195(42), HT 96(21), ChT +HT 104(23) | |
| Briasoulis E [40] | 13(13) | NA | NA | 6(6) | 7(7) | NA | 104(100) | NA | BMA 70(67), RT 104(100), ChT 61(59), HT 53(51) |
| Plunkett TA [42] | NA | NA | 576(67) | 296(35) | 64(8) | 162(19) | 576(67) | NA | RT 576(67) |
| Domchek SM [43] | 369(51) | 2.25 | NA | 57(8) | 61(9) | 73(10) | 293(41) | 56(8) | BMA 310(4), RT 293(41), Sur 56(8) |
SREs, skeletal-related events; SREFI, skeletal-related events-free interval; BP: bone pain; PF, pathological fractures; SCC, spinal cord compression; TIH, tumor-induced hypercalcemia; BMA, bone-modifying agents; RT, radiation therapy; HT, hormonal therapy; MT, molecular-targeted therapy; ChT, chemotherapy; Sur, surgery; yr, year.
NA, not available; F/U, follow-up.
a
With osteoporosis.
b
Without osteoporosis.